Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Active not recruiting 3Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Polycystic Ovary Syndrome 2Breast Neoplasms 2Hyperandrogenism 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Estradiol × Clear all
NCT01083641 2019-12-09

Estrogen for Triple Negative Breast Cancer

University of Wisconsin, Madison

Phase 2 Terminated
17 enrolled 10 charts
Breast

Breast Neoplasms

NCT00661531 2017-04-12

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Georgetown University

Phase 2 Terminated
11 enrolled 8 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡